GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Core One Labs Inc (XCNQ:COOL) » Definitions » Cash Flow from Financing

Core One Labs (XCNQ:COOL) Cash Flow from Financing

: C$1.94 Mil (TTM As of Dec. 2023)
View and export this data going back to 2011. Start your Free Trial

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Core One Labs paid C$0.00 Mil more to buy back shares than it received from issuing new shares. It received C$0.00 Mil from issuing more debt. It paid C$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received C$0.00 Mil from paying cash dividends to shareholders. It received C$0.00 Mil on other financial activities. In all, Core One Labs spent C$0.00 Mil on financial activities for the three months ended in Dec. 2023.


Core One Labs Cash Flow from Financing Historical Data

The historical data trend for Core One Labs's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core One Labs Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Flow from Financing
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.13 15.50 6.34 4.43 3.59

Core One Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Sep23 Dec23
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.26 1.94 - -

Core One Labs Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Core One Labs's Cash from Financing for the fiscal year that ended in Dec. 2021 is calculated as:

Core One Labs's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Core One Labs  (XCNQ:COOL) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Core One Labs's issuance of stock for the three months ended in Dec. 2023 was C$0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Core One Labs's repurchase of stock for the three months ended in Dec. 2023 was C$0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Core One Labs's net issuance of debt for the three months ended in Dec. 2023 was C$0.00 Mil. Core One Labs received C$0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Core One Labs's net issuance of preferred for the three months ended in Dec. 2023 was C$0.00 Mil. Core One Labs paid C$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Core One Labs's cash flow for dividends for the three months ended in Dec. 2023 was C$0.00 Mil. Core One Labs received C$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Core One Labs's other financing for the three months ended in Dec. 2023 was C$0.00 Mil. Core One Labs received C$0.00 Mil on other financial activities.


Core One Labs Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Core One Labs's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Core One Labs (XCNQ:COOL) Business Description

Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 800, Vancouver, BC, CAN, V6E 3T5
Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.